文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌治疗方案的比较有效性:癌症登记数据回顾性分析的局限性

Comparative Effectiveness of Prostate Cancer Treatment Options: Limitations of Retrospective Analysis of Cancer Registry Data.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-08-09

该研究利用SEER-MHOS关联数据集的3102例前列腺癌患者,通过潜在类别分析识别健康状态最佳组(占57%,10年总生存率67%),并在该组内比较不同治疗的总生存。结果显示,健康最佳组中10年总生存率因治疗不同而异:无局部治疗55%、外照射放疗69%、近距离放疗76%、根治性前列腺切除术85%,生存曲线在随访4年时分离。作者结论认为,即便有详细健康状态信息,回顾性分析仍无法完全校正治疗组间的患者选择偏倚。

要点

  • 健康最佳组占队列57%,10年总生存率67%。
  • 健康最佳组10年总生存率:无局部治疗55%、外照射放疗69%、近距离放疗76%、根治性前列腺切除术85%。
  • 3个治疗组的生存曲线在随访4年时分离。

核心结论

  • 尽管SEER-MHOS提供了详细健康状态信息,该回顾性分析仍无法完全校正前列腺癌治疗组间的患者选择偏倚。
  • 这些发现凸显了使用人群基础数据集的回顾性研究的重要局限性,并提醒应谨慎解读结果。

研究设计与样本

  • 研究分析了SEER-MHOS数据集中3102例前列腺癌患者,该数据集关联了SEER数据库与MHOS数据库,包含患者报告的合并症和功能受限的详细信息。
  • 采用潜在类别分析识别合并症负担和功能受限最小的最健康组,并在该组内使用Kaplan-Meier法比较不同治疗的总生存。

主要发现

  • 潜在类别分析识别出3个不同的健康组;最健康组占队列57%,10年总生存率为67%。
  • 其他健康组有更高的合并症或功能受限比例。
  • 在最健康组中,10年总生存率因治疗组而异:无局部治疗55%、外照射放疗69%、近距离放疗76%、根治性前列腺切除术85%。
  • 3个治疗组的生存曲线在随访4年时分离。

局限性

  • 尽管SEER-MHOS有详细健康状态信息,该回顾性分析仍无法完全校正前列腺癌治疗组间的患者选择偏倚。
  • 这些发现凸显了使用人群基础数据集的回顾性研究的重要局限性。
  • 结果解读应谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Retrospective analyses of cancer registry and institutional data have consistently found better survival after radical prostatectomy versus radiation therapy, which contrasts with findings from a randomized trial. This is likely because of the inability of retrospective studies to fully account for comorbidity differences across treatment groups because of the lack of detailed data in the registries. We use a unique population-based data set with detailed data regarding comorbidities and functional limitations to assess whether this can provide valid comparisons of survival across prostate cancer treatment groups. METHODS AND MATERIALS: The Surveillance, Epidemiology, and End Results (SEER)-Medicare Health Outcomes Survey (MHOS) data set results from a linkage between the SEER database and the MHOS database, which includes detailed information regarding patient-reported comorbidity and functional limitations. We analyzed 3102 patients with prostate cancer in SEER-MHOS and used latent class analysis to identify the healthiest group with minimal comorbidity burden and functional limitations. Among the healthiest group, we examined overall survival across treatments using the Kaplan-Meier method. RESULTS: Three distinct health groups were identified using latent class analysis; the healthiest group comprised 57% of the cohort and had a 10-year overall survival of 67%. Other health groups had higher rates of comorbidities or functional limitations. Among the healthiest group, 10-year overall survival differed across treatment groups: no local treatment (55%), external beam radiation therapy (69%), brachytherapy (76%), and radical prostatectomy (85%). Survival curves for the 3 treated groups separated at 4 years of follow-up. CONCLUSIONS: Despite the detailed health status information available in SEER-MHOS, our retrospective analysis could not fully account for patient selection biases across prostate cancer treatment groups. These findings highlight an important limitation of retrospective studies using population-based data sets and serve as a reminder to interpret results with caution.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Pearlstein KA, Basak R, Chen RC, et al. Comparative Effectiveness of Prostate Cancer Treatment Options: Limitations of Retrospective Analysis of Cancer Registry Data. Int J Radiat Oncol Biol Phys. 2018. PMID: 30099129. doi:10.1016/j.ijrobp.2018.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。